Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Kimmie Ng

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0631-1494; OpenAlex author ID A5077382664. Sources: OpenAlex.

Their work

Papers
46 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
147
Papers, trials and grants by year

2012: 2 papers · 2013: 1 paper · 2014: 1 paper · 2015: 1 paper · 2016: 3 papers · 2017: 3 papers · 2018: 6 papers · 2019: 4 papers · 2020: 6 papers · 2021: 4 papers · 2022: 2 papers · 2023: 7 papers · 2024: 1 paper · 2025: 1 paper · 2026: 4 papers

Papers 46

  1. Polygenic scores for risk of pancreatic ductal adenocarcinoma: evaluation of novel and published models. Co-author DOI 10.1038/s41698-026-01479-x↗
  2. Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomized, multiarm, run-in phase trial. Co-author DOI 10.1038/s43018-026-01165-8↗
  3. Different diabetes types and pancreatic ductal adenocarcinoma: a Mendelian randomization and pathway/gene-set analysis. Co-author DOI 10.1093/jnci/djaf308↗
  4. A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2. Co-author DOI 10.1158/1078-0432.ccr-24-3766↗
  5. Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreat… Co-author DOI 10.1200/po-25-00332↗
  6. Protein biomarkers and alternatively methylated cell-free DNA detect early stage pancreatic cancer. Co-author DOI 10.1136/gutjnl-2023-331074↗
  7. A blood-based metabolomic signature predictive of risk for pancreatic cancer. Co-author DOI 10.1016/j.xcrm.2023.101194↗
  8. Pancreatic cancer is associated with medication changes prior to clinical diagnosis. Co-author DOI 10.1038/s41467-023-38088-2↗
  9. Adipose tissue and skeletal muscle wasting precede clinical diagnosis of pancreatic cancer. Co-author DOI 10.1038/s41467-023-40024-3↗
  10. Sex-Specific Associations between Adiponectin and Leptin Signaling and Pancreatic Cancer Survival. Co-author DOI 10.1158/1055-9965.epi-23-0505↗
  11. Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-22-3930↗
  12. A Phase I Expansion Cohort Study Evaluating the Safety and Efficacy of the CHK1 Inhibitor LY2880070 with Low-dose Gemcitabine in Patients with Metastatic Pancr… Co-author DOI 10.1158/1078-0432.ccr-23-2005↗
  13. Helicobacter pylori Seropositivity, ABO Blood Type, and Pancreatic Cancer Risk From 5 Prospective Cohorts. Co-author DOI 10.14309/ctg.0000000000000573↗
  14. The age-dependent association of risk factors with pancreatic cancer. Co-author DOI 10.1016/j.annonc.2022.03.276↗
  15. Neoadjuvant Chemotherapy Is Associated with Altered Immune Cell Infiltration and an Anti-Tumorigenic Microenvironment in Resected Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-22-1125↗
  16. Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer. Co-author DOI 10.1016/j.cell.2021.11.017↗
  17. Lead-Time Trajectory of CA19-9 as an Anchor Marker for Pancreatic Cancer Early Detection. Co-author DOI 10.1053/j.gastro.2020.11.052↗
  18. Prediagnostic Inflammation and Pancreatic Cancer Survival. Co-author DOI 10.1093/jnci/djab040↗
  19. Smoking Modifies Pancreatic Cancer Risk Loci on 2q21.3. Co-author DOI 10.1158/0008-5472.can-20-3267↗
  20. Diabetes, Weight Change, and Pancreatic Cancer Risk. Co-author DOI 10.1001/jamaoncol.2020.2948↗
  21. A Transcriptome-Wide Association Study Identifies Novel Candidate Susceptibility Genes for Pancreatic Cancer. Co-author DOI 10.1093/jnci/djz246↗
  22. Genome-Wide Association Study Data Reveal Genetic Susceptibility to Chronic Inflammatory Intestinal Diseases and Pancreatic Ductal Adenocarcinoma Risk. Co-author DOI 10.1158/0008-5472.can-20-0447↗
  23. Insulin-Like Growth Factor-1 Receptor Expression and Disease Recurrence and Survival in Patients with Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1055-9965.epi-19-1315↗
  24. Genetic and Circulating Biomarker Data Improve Risk Prediction for Pancreatic Cancer in the General Population. Co-author DOI 10.1158/1055-9965.epi-19-1389↗
  25. Genome-Wide Gene-Diabetes and Gene-Obesity Interaction Scan in 8,255 Cases and 11,900 Controls from PanScan and PanC4 Consortia. Co-author DOI 10.1158/1055-9965.epi-20-0275↗
  26. Phase 1 dose-escalation study of momelotinib, a Janus kinase 1/2 inhibitor, combined with gemcitabine and nab-paclitaxel in patients with previously untreated … Co-author DOI 10.1007/s10637-018-0650-5↗
  27. Family history of cancer, Ashkenazi Jewish ancestry, and pancreatic cancer risk. Co-author DOI 10.1038/s41416-019-0426-5↗
  28. Postdiagnosis Loss of Skeletal Muscle, but Not Adipose Tissue, Is Associated with Shorter Survival of Patients with Advanced Pancreatic Cancer. Co-author DOI 10.1158/1055-9965.epi-19-0370↗
  29. Prediagnostic Leukocyte Telomere Length and Pancreatic Cancer Survival. Co-author DOI 10.1158/1055-9965.epi-19-0577↗
  30. Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamaoncol.2017.3420↗
  31. Statin use and pancreatic cancer risk in two prospective cohort studies. Co-author DOI 10.1007/s00535-018-1430-x↗
  32. Prediagnosis Use of Statins Associates With Increased Survival Times of Patients With Pancreatic Cancer. Co-author DOI 10.1016/j.cgh.2018.02.022↗
  33. Plasma inflammatory cytokines and survival of pancreatic cancer patients. Last author DOI 10.1038/s41424-018-0008-5↗
  34. Regular Use of Aspirin or Non-Aspirin Nonsteroidal Anti-Inflammatory Drugs Is Not Associated With Risk of Incident Pancreatic Cancer in Two Large Cohort Studie… Co-author DOI 10.1053/j.gastro.2017.12.001↗
  35. Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. Co-author DOI 10.1158/2159-8290.cd-18-0275↗
  36. Lymph node metastases in resected pancreatic ductal adenocarcinoma: predictors of disease recurrence and survival. Co-author DOI 10.1038/bjc.2017.349↗
  37. Leucocyte telomere length, genetic variants at the TERT gene region and risk of pancreatic cancer. Co-author DOI 10.1136/gutjnl-2016-312510↗
  38. Cigarette Smoking and Pancreatic Cancer Survival. Co-author DOI 10.1200/jco.2016.71.2026↗
  39. Circulating Metabolites and Survival Among Patients With Pancreatic Cancer. Co-author DOI 10.1093/jnci/djv409↗
  40. Pancreatic Cancer Risk Associated with Prediagnostic Plasma Levels of Leptin and Leptin Receptor Genetic Polymorphisms. Co-author DOI 10.1158/0008-5472.can-16-1699↗
  41. Prediagnostic Plasma 25-Hydroxyvitamin D and Pancreatic Cancer Survival. Co-author DOI 10.1200/jco.2015.66.3005↗
  42. Survival among patients with pancreatic cancer and long-standing or recent-onset diabetes mellitus. Co-author DOI 10.1200/jco.2014.57.5688↗
  43. Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma. Co-author DOI 10.1634/theoncologist.2014-0086↗
  44. Prediagnostic body mass index and pancreatic cancer survival. Co-author DOI 10.1200/jco.2013.51.7532↗
  45. A phase 2 study of oral MKC-1, an inhibitor of importin-β, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancer. Co-author DOI 10.1007/s10637-011-9708-3↗
  46. Plasma 25-hydroxyvitamin D and risk of pancreatic cancer. First author DOI 10.1158/1055-9965.epi-11-0836↗

Closest collaborators

The 25 strongest of 147 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Brian Matthew Wolpin · 38 shared papers, 2012–2026 · strength 3.30
  2. Chen Yuan · 27 shared papers, 2013–2024 · strength 2.19
  3. Ana Babić · 25 shared papers, 2016–2024 · strength 2.14
  4. Jonathan Andrew Nowak · 18 shared papers, 2017–2026 · strength 1.93
  5. Douglas Adam Rubinson · 22 shared papers, 2013–2026 · strength 1.88
  6. Kimberly J. Perez · 13 shared papers, 2019–2026 · strength 1.60
  7. Charles S. Fuchs · 23 shared papers, 2012–2023 · strength 1.58
  8. Edward L. Giovannucci · 20 shared papers, 2012–2023 · strength 1.49
  9. Peter Kraft · 20 shared papers, 2012–2023 · strength 1.49
  10. Andrew J. Aguirre · 12 shared papers, 2018–2026 · strength 1.44
  11. Vicente Morales‐Oyarvide · 16 shared papers, 2016–2022 · strength 1.06
  12. James M. Cleary · 8 shared papers, 2014–2026 · strength 0.99
  13. Harshabad Singh · 6 shared papers, 2022–2026 · strength 0.88
  14. Thomas E. Clancy · 10 shared papers, 2015–2024 · strength 0.87
  15. JoAnn E. Manson · 12 shared papers, 2012–2023 · strength 0.86
  16. Srivatsan Raghavan · 6 shared papers, 2021–2026 · strength 0.85
  17. Natalia I. Khalaf · 11 shared papers, 2017–2023 · strength 0.84
  18. Qiao-Li Wang Wang · 6 shared papers, 2022–2024 · strength 0.79
  19. Andrea J. Bullock · 7 shared papers, 2017–2026 · strength 0.79
  20. Matthew B.B. Yurgelun · 5 shared papers, 2019–2026 · strength 0.67
  21. Alice A. Lee · 5 shared papers, 2022–2023 · strength 0.66
  22. Leah H. Biller · 4 shared papers, 2023–2026 · strength 0.60
  23. Michael Hayden Rosenthal · 5 shared papers, 2019–2023 · strength 0.57
  24. Zhi Rong Qian · 11 shared papers, 2013–2018 · strength 0.54
  25. ANDREA C Enzinger · 3 shared papers, 2025–2026 · strength 0.52

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.